Recent Applications and Strategies in Nanotechnology for Lung Diseases

Overview

Journal Nano Res

Date 2021 Jan 18

PMID 33456721

Citations 22

Authors

Wenhao Zhong

Xinyu Zhang

Yunxin Zeng

Dongjun Lin

Jun Wu

Affiliations

Soon will be listed here.

Abstract

Lung diseases, including COVID-19 and lung cancers, is a huge threat to human health. However, for the treatment and diagnosis of various lung diseases, such as pneumonia, asthma, cancer, and pulmonary tuberculosis, are becoming increasingly challenging. Currently, several types of treatments and/or diagnostic methods are used to treat lung diseases; however, the occurrence of adverse reactions to chemotherapy, drug-resistant bacteria, side effects that can be significantly toxic, and poor drug delivery necessitates the development of more promising treatments. Nanotechnology, as an emerging technology, has been extensively studied in medicine. Several studies have shown that nano-delivery systems can significantly enhance the targeting of drug delivery. When compared to traditional delivery methods, several nanoparticle delivery strategies are used to improve the detection methods and drug treatment efficacy. Transporting nanoparticles to the lungs, loading appropriate therapeutic drugs, and the incorporation of intelligent functions to overcome various lung barriers have broad prospects as they can aid in locating target tissues and can enhance the therapeutic effect while minimizing systemic side effects. In addition, as a new and highly contagious respiratory infection disease, COVID-19 is spreading worldwide. However, there is no specific drug for COVID-19. Clinical trials are being conducted in several countries to develop antiviral drugs or vaccines. In recent years, nanotechnology has provided a feasible platform for improving the diagnosis and treatment of diseases, nanotechnology-based strategies may have broad prospects in the diagnosis and treatment of COVID-19. This article reviews the latest developments in nanotechnology drug delivery strategies in the lungs in recent years and studies the clinical application value of nanomedicine in the drug delivery strategy pertaining to the lung.

Citing Articles

Innovative approaches to asthma treatment: harnessing nanoparticle technology.

Goswami V, Sodhi K, Singh C Discov Nano. 2025; 20(1):21.

PMID: 39922940 PMC: 11807046. DOI: 10.1186/s11671-025-04211-z.

Innovating non-small cell lung cancer treatment with novel TM-GL/NPs nanoparticles for Glycitin delivery.

Liu C, Zhao J, Liu J, Wang Y Cell Biol Toxicol. 2025; 41(1):41.

PMID: 39921782 PMC: 11807077. DOI: 10.1007/s10565-024-09972-4.

Recent advances in self-targeting natural product-based nanomedicines.

Liu H, Jin X, Liu S, Liu X, Pei X, Sun K J Nanobiotechnology. 2025; 23(1):31.

PMID: 39833846 PMC: 11749302. DOI: 10.1186/s12951-025-03092-9.

Respiratory delivered vaccines: Current status and perspectives in rational formulation design.

Wu L, Xu W, Jiang H, Yang M, Cun D Acta Pharm Sin B. 2025; 14(12):5132-5160.

PMID: 39807330 PMC: 11725141. DOI: 10.1016/j.apsb.2024.08.026.

Quality by Design in Pulmonary Drug Delivery: A Review on Dry Powder Inhaler Development, Nanotherapy Approaches, and Regulatory Considerations.

Sutar A, Verma R, Shukla R AAPS PharmSciTech. 2024; 25(6):178.

PMID: 39095623 DOI: 10.1208/s12249-024-02900-z.

References

de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

Cook R, Pannu R, Kellaway I . Novel sustained release microspheres for pulmonary drug delivery. J Control Release. 2005; 104(1):79-90. DOI: 10.1016/j.jconrel.2005.01.003. View

Sharma R, Kaur A, Sharma A, Dilbaghi N, Sharma A . Nano-Based Anti-Tubercular Drug Delivery and Therapeutic Interventions in Tuberculosis. Curr Drug Targets. 2015; 18(1):72-86. DOI: 10.2174/1389450116666150804110238. View

Sears C, Cooney S, Chin-Sinex H, Mendonca M, Turchi J . DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer. DNA Repair (Amst). 2016; 40:35-46. PMC: 4852375. DOI: 10.1016/j.dnarep.2016.02.004. View

Doroudian M, MacLoughlin R, Poynton F, Prina-Mello A, Donnelly S . Nanotechnology based therapeutics for lung disease. Thorax. 2019; 74(10):965-976. DOI: 10.1136/thoraxjnl-2019-213037. View

Lai S, Wang Y, Wirtz D, Hanes J . Micro- and macrorheology of mucus. Adv Drug Deliv Rev. 2009; 61(2):86-100. PMC: 2736374. DOI: 10.1016/j.addr.2008.09.012. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

di SantAgnese P, DAVIS P . Research in cystic fibrosis (third of three parts). N Engl J Med. 1976; 295(11):597-602. DOI: 10.1056/NEJM197609092951105. View

Dua K, Shukla S, Tekade R, Hansbro P . Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases?. Drug Deliv Transl Res. 2016; 7(1):179-187. DOI: 10.1007/s13346-016-0349-0. View

10.

Mamary A, Criner G . Tiotropium bromide for chronic obstructive pulmonary disease. Expert Rev Respir Med. 2010; 3(3):211-20. DOI: 10.1586/ers.09.19. View

11.

Vij N . Nano-based rescue of dysfunctional autophagy in chronic obstructive lung diseases. Expert Opin Drug Deliv. 2016; 14(4):483-489. DOI: 10.1080/17425247.2016.1223040. View

12.

Kato H, Hagihara M, Hirai J, Sakanashi D, Suematsu H, Nishiyama N . Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen. Drugs R D. 2017; 17(1):177-187. PMC: 5318333. DOI: 10.1007/s40268-016-0165-5. View

13.

Ehsan Z, Clancy J . Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. Future Microbiol. 2015; 10(12):1901-12. PMC: 4944396. DOI: 10.2217/fmb.15.117. View

14.

Liu C, Lyon C, Bu Y, Deng Z, Walters E, Li Y . Clinical Evaluation of a Blood Assay to Diagnose Paucibacillary Tuberculosis via Bacterial Antigens. Clin Chem. 2018; 64(5):791-800. PMC: 5996152. DOI: 10.1373/clinchem.2017.273698. View

15.

Quesada-Gonzalez D, Merkoci A . Nanomaterial-based devices for point-of-care diagnostic applications. Chem Soc Rev. 2018; 47(13):4697-4709. DOI: 10.1039/c7cs00837f. View

16.

Moro M, Di Paolo D, Milione M, Centonze G, Bornaghi V, Borzi C . Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. J Control Release. 2019; 308:44-56. DOI: 10.1016/j.jconrel.2019.07.006. View

17.

Wu L, Shan W, Zhang Z, Huang Y . Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties. Adv Drug Deliv Rev. 2017; 124:150-163. DOI: 10.1016/j.addr.2017.10.001. View

18.

Zhang X, Zhao M, Cao N, Qin W, Zhao M, Wu J . Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment. Biomater Sci. 2020; 8(7):1885-1896. DOI: 10.1039/c9bm01927h. View

19.

Chen X, Huang W, Wong B, Yin L, Wong Y, Xu M . Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomedicine. 2012; 7:1139-48. PMC: 3299201. DOI: 10.2147/IJN.S28011. View

20.

Singh L, Kruger H, Maguire G, Govender T, Parboosing R . The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis. 2017; 4(4):105-131. PMC: 5507392. DOI: 10.1177/2049936117713593. View